: iStockAnalyst.com Symbols Feed

Swing Trades For The Day - High Fliers

Wed, 25 Nov 2009 13:21:49 GMT

I'm back in better health today and I've got a bunch of swing trading candidates for the model portfolio. I'm choosing to center to stocks with a lot of momentum on the upside, as index futures are strong this morning (Asia closed out pretty well, while Europe is strong), and a breakout in the S&P 500 above 1,112 would be a momentum-based move. I'd expect stocks with strong momentum to outperform the market. On the other hand, since[More...]

Gloomy Put Options Posturing On Financials ETF

Mon, 02 Nov 2009 20:48:17 GMT

Today's tickers: XLF, ETFC, CF, HGSI, EEM, BEBE, SMH, VRTX, HGSI, F & LDK[More...]

Innovative Drug Companies Headline The Gainers

Mon, 02 Nov 2009 20:44:13 GMT

For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs and medical devices come from America. It is worth remembering that even with all the problems troubling the health care system, innovation continues to be a bright spot. Three of the biggest gains among individual stocks on Monday were from U.S. companies in the pharmaceutical sector largely because of this sort of innovation.[More...]

Vertex Strapped For Cash (NASDAQ: VRTX)

Thu, 01 Oct 2009 17:32:45 GMT

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) sold the rights to its key milestone payments for their hepatitis C drug in development telaprevir, worth up to $95 million.[More...]

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Play Likely To Reward Investors

Fri, 18 Sep 2009 13:25:00 GMT

Since touching a low of $26.23 on April 7, 2009, Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company, has nicely rebounded closing September 17, at $37.95 – annual return in excess of 100%.[More...]

Pharmaceuticals & Biotech - Industry Outlook

Tue, 09 Jun 2009 12:05:35 GMT

The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including: Pfizer (PFE, 7.5x), Eli Lilly (LLY,[More...]

The Market Is At A Crossroads

Sat, 04 Apr 2009 15:33:00 GMT

There are signs of both a potential market recovery (the beginning of a larger bull rally), and signs that this recent 20%+ run-up was nothing more than a bear market rally. The good news is that there will be plenty of opportunities going forward, regardless of which of the above scenarios plays out. Bull Market Rally Scenario The move that we have recently seen, i.e., 24.82% in the Dow Jones Industrial Average ($DJI), 26.82% in the S&P 500 (SPX), and 28.26% in the Nasdaq (COMP), from the lows made in early March to the highs made just 4 weeks later,[More...]

How To Spend $95 in Biotech

Wed, 18 Mar 2009 03:19:00 GMT

Sometime during the middle of the year, Genentech (DNA) shareholders are going to get $95 in cash for each share of Genentech stock they own. In total, nearly $47 billion in funds are expected to be returned to biotechnology investors. We've come up with an effective "basket approach" to re-deploy those funds back into the biotech sector -- in search of the next Genentech. Antisense Makes a Lot of Sense For a little over $13, investors can pick up one share of Isis Pharmaceuticals (ISIS). Isis is the market leader in antisense[More...]

Roche Keeps M&A Party Rolling With $46.8 Billion Deal For Genentech

Fri, 13 Mar 2009 14:34:00 GMT

By Don Miller Associate Editor Money Morning Big Pharma’s rapidly accelerating consolidation pattern snowballed yesterday (Thursday) as Roche Holding AG (ADR: RHHBY) struck a deal to... Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. Money moves markets. But Money Morning lets you move first. [More...]

Pharmaceuticals

Tue, 10 Feb 2009 18:38:00 GMT

Large pharmaceutical companies all seem to be in a similar boat heading into 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds as well. Revenue growth is non-existent, and earnings growth is being driven primarily by cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including Pfizer (PFE, 7x), Eli Lilly (LLY, 9x), Merck ([More...]

Earnings roundup: Heartland Financial, Masco

Mon, 26 Oct 2009 22:47:00 GMT

Among the earnings stories for Monday, Oct. 26, from AP Financial News:
DUBUQUE, Iowa (AP) - Community bank Heartland Financial USA Inc. said Monday that higher loan losses narrowed its profit in the third quarter.
CAMBRIDGE, Mass. (AP) - Vertex Pharmaceuticals Inc. reported a larger third-quarter loss on Monday, as revenue fell and the company spent more money to support the launch of its hepatitis C drug candidate.

: iStockAnalyst.com Symbols Feed

Swing Trades For The Day - High Fliers

Gloomy Put Options Posturing On Financials ETF

Innovative Drug Companies Headline The Gainers

Vertex Strapped For Cash (NASDAQ: VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Play Likely To Reward Investors

Pharmaceuticals & Biotech - Industry Outlook

The Market Is At A Crossroads

How To Spend $95 in Biotech

Roche Keeps M&A Party Rolling With $46.8 Billion Deal For Genentech

Pharmaceuticals

Earnings roundup: Heartland Financial, Masco

Movers: Home Depot, Wellcare, Lehman Brothers, Target

The Fortune Financial Undertakes Review of Stocks in the Healthcare and Services Sectors

Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Adams Global Growth Conference

BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update

Vertex Pharmaceuticals Reports Second Quarter 2009 Financial Results and Highlights Recent Clinical Progress and Business Development Activity

Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation Amend Agreement to Develop and Commercialize Telaprevir in Asia

Vertex Pharmaceuticals Announces the Date of its Second Quarter 2009 Financial Results Conference Call and Webcast

Third Rock Ventures Expands Team With Biotech Veterans

BenchmarkJournal.Com Free Analyst Review for SWHC, AMAT, SYNA, VRTX, CPHD and AKAM

Vertex Pharmaceuticals Announces Intention to Sell Its Rights to European Milestone Payments for Telaprevir

Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals’ Board of Directors

Form 4 VERTEX PHARMACEUTICALS For: Nov 25 Filed by: BOGER JOSHUA S (10K)

Form 4 VERTEX PHARMACEUTICALS For: Nov 18 Filed by: BOGER JOSHUA S (10K)

Form 4 VERTEX PHARMACEUTICALS For: Nov 17 Filed by: Kelly Lisa (10K)

Form 4 VERTEX PHARMACEUTICALS For: Nov 11 Filed by: BOGER JOSHUA S (10K)

Form 4 BOGER JOSHUA S For: Oct 27 (10K)

Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: SMITH IAN F (10K)

Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: Sachdev Amit (10K)

Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: MUELLER PETER (10K)

Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: Kelly Lisa (10K)

Form 4 VERTEX PHARMACEUTICALS For: Oct 22 Filed by: BOGER KENNETH S (10K)